Recent Finacing
Recent Raise
Iterion Therapeutics, a clinical-stage biotech developing Tegavivint—a TBL1-binding inhibitor of nuclear β-catenin that silences Wnt-pathway signaling—has a Phase 1/2a desmoid tumor trial and programs in AML, NSCLC, pediatric cancers.
